• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Discovery shows promise for treating Huntington’s Disease

Bioengineer by Bioengineer
August 5, 2020
in Chemistry
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Scientists at EPFL’s Brain Mind Institute have identified an enzyme that can play a central role in developing a new route of treatment for Huntington’s Disease.

IMAGE

Credit: R.N. Hegde and H. Lashuel (EPFL)

Huntington disease is a progressive and aggressively debilitating brain disorder that causes uncontrolled movements, psychological problems, and loss of cognition. It is caused by a mutation in the gene that encodes the protein huntingtin, causing it to build an abnormally long tail of the amino acid glutamine. This tail prevents huntingtin from folding properly and as a result it aggregates inside neurons of the brain, and eventually kills them.

Huntington’s affects hundreds of thousands of people in the world, and as an “autosomal dominant” disease, a person only needs one copy of the mutant huntingtin gene to develop the disease. Scientists in both academia and industry are exploring different approaches to tackle the disease. The most popular strategy is to lower the levels of huntingtin or to inhibit its aggregation – or a combination of both. The way to do this is to either “silence” the huntingtin gene or to activate cellular mechanisms that promote the degradation of the protein itself.

Now, scientists at the lab of Professor Hilal Lashuel at EPFL have identified a new enzyme that does both. The enzyme, called “TBK1”, plays a central role in regulating the degradation and clearance of the huntingtin protein and introduces chemical modifications that block its aggregation. “We believe that this represents a viable target for the development of possible treatment of Huntington’s disease,” says Lashuel.

The TBK1 enzyme is a “kinase”. In the cell, kinases are enzymes that add phosphate groups to various biomolecules like proteins or DNA. In the world of the cell, phosphate groups are energy-carriers, so adding one essentially “turns on” the receiving molecule.

Previous studies have shown that artificially adding phosphate groups to huntingtin can stop it from aggregating and causing Huntington’s disease. “However, to explore the therapeutic potential of phosphorylation, we needed to identify the natural kinases that do the job inside the cell,” says Lashuel. “After screening hundreds of kinases, we were excited to identify TBK1, because it did the job with high specificity and efficiency.”

The researchers found that, when TBK1 adds a phosphate group anywhere in the first 17 amino acids of huntingtin, it inhibits its ability to aggregate. This was the case for both the normal and mutated versions of huntingtin.

In addition, increasing TBK1 levels in cells leads to over-phosphorylation of a specific amino acid (a serine) in the huntingtin chain. This stabilizes the protein and stops it from aggregating.

Finally, TBK1 was also found to signal the cell to degrade and clean out huntingtin before it aggregates. This lowers overall huntingtin levels, which results in reducing aggregate formation inside the cell.

Encouraged by their findings, the scientists then moved onto an animal model of Huntington’s Disease: the worm C. elegans. What they found corroborated their previous data: Over-expressing the TBK1 kinase protected against mutant huntingtin toxicity in the worm, preventing the development of Huntington’s Disease. The researchers got similar results in cultured neurons.

“Our work shows that TBK1-mediated increase in phosphorylation and/or promoting mutant huntingtin autophagic clearance represent viable therapeutic strategies for the treatment of Huntington’s Disease,” says Ramanath Hegde, who led the study.

“We are very excited about these findings,” says Lashuel. “TBK1 has also been shown to regulate the clearance and degradation of proteins implicated in other neurodegenerative diseases. Mutations in TBK1 have also recently been linked to ALS and result in impaired autophagy, which leads to the accumulation of aggregates. Our goal is to find small molecules or drug pathways and to develop these for multiple neurodegenerative diseases.”

###

Other contributors

IRBM Science Park, Italy

Johns Hopkins University School of Medicine

EPFL Laboratory of Integrative and Systems Physiology

University College London

University of Auckland

Media Contact
Hilal Lashuel
[email protected]

Original Source

https://actu.epfl.ch/news/discovery-shows-promise-for-treating-huntington-s-

Related Journal Article

http://dx.doi.org/10.15252/embj.2020104671

Tags: AlzheimerCell BiologyMedicine/HealthMicrobiologyMolecular Biologyneurobiology
Share12Tweet8Share2ShareShareShare2

Related Posts

Metal–Sulfur Sites Boost MOF Hydrogenation Catalysis

Metal–Sulfur Sites Boost MOF Hydrogenation Catalysis

August 3, 2025
Bright Excitons Enable Optical Spin State Control

Bright Excitons Enable Optical Spin State Control

August 3, 2025

Flame Synthesis Creates Custom High-Entropy Metal Nanomaterials

August 2, 2025

Innovative Acid-Base Bifunctional Catalyst Enhances Production of Essential Lithium-Ion Battery Material

August 1, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    52 shares
    Share 21 Tweet 13
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Micro- and Nanoplastics Threaten Early-Life Health: Risks

PI-RADS v2.1 Plus Amide Transfer Boosts Detection

Satellite and AI Unite to Estimate Underwater Sound Speed

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.